Weight loss drugs effects on cardiometabolic profile remains unproven.

  Approved weight-loss medications have only modest effects on cardiovascular risk. Igho Onakpoya One rationale for the development and marketing of weight loss drugs is that their use will improve cardiac risk factors. In a recent systematic review and network meta-analysis [1]  of 28 randomised controlled trials (29,018 participants), the authors concluded that the effects […]

Read More…

Seven ways to ensure faster removal of harmful medicines

  Harmful medicines sometimes stay on the market for longer than they should. When that happens, people are unnecessarily exposed to medicines that may adversely affect their health. Igho Onakpoya The benefit-harm balance of new medicines is often not fully known at the time marketing licences are granted. More information about harms often becomes apparent […]

Read More…

Rare adverse events in clinical trials: understanding the rule of three

  Investigators should report rare and very rare adverse events in clinical trials: Igho Onakpoya reports why it is important that all events are reported irrespective of their frequency.   Even though they may not give a signal in any single trial, a meta-analysis could reveal potentially important drug-adverse event associations that might require further […]

Read More…